Bristol-Myers Squibb: EU Patent Law T 0715/24 Claim Construction Ruling

• Bristol-Myers Squibb (BMS) appealed to the Board of Appeal in T 0715/24, seeking to redefine 'monotherapy' in cancer treatment patents.
• The case revolves around whether a definition in the description can override an otherwise clear meaning in the claims, as per G 1/24 EU patent interpretation.
• T 0715/24 has significant implications for claim construction in EU patent law and may set a precedent for how courts approach definitions in descriptions versus clear claim language.

The question remains whether a definition in the description can override an otherwise clear meaning in the claims.

In the recent T 0715/24 case, Bristol-Myers Squibb (BMS) appealed to the Board of Appeal, seeking to redefine the scope of their patent. The central issue revolved around the interpretation of the term 'monotherapy' in the context of cancer treatment. BMS argued that a negative feature, combined with a specific paragraph in the description, should take precedence over the clear meaning of the word in the claims.

The Board of Appeal was tasked with determining whether a definition in the description can override an otherwise unambiguous claim interpretation. This question has significant implications for patent law and the way courts approach claim construction.

The case is closely tied to the EU's G 1/24 ruling, which emphasizes that the description must be consulted when interpreting claims. However, this raises a crucial question: can a definition in the description supersede an otherwise clear meaning in the claims? This ambiguity has sparked debate among patent experts and lawyers, who are now watching T 0715/24 as a key precedent for claim construction in EU patent law.

The case also highlights the importance of understanding how definitions in the description interact with clear meanings in the claims. As courts continue to grapple with this issue, it is essential for lawyers to stay attuned to the implications of T 0715/24 on claim construction and its potential impact on patent litigation.

The outcome of T 0715/24 has far-reaching consequences for patent holders, applicants, and courts navigating EU patent law. If the Board of Appeal rules in favor of BMS, it could set a precedent that allows definitions in the description to override clear claim interpretations. This would fundamentally alter the way courts approach claim construction, potentially leading to more disputes and appeals.

Conversely, if the Board rejects BMS's argument, it would reinforce the importance of clear claim language and provide much-needed clarity for patent applicants and holders. Either outcome will have significant implications for the patent landscape in Europe, making T 0715/24 a closely watched case among lawyers and experts.

Lawyers should watch for the implications of T 0715/24 on claim construction in EU patent law, particularly how definitions in the description may interact with clear meanings in the claims.

Source: Original reporting via Briefly